{"id":314268,"date":"2025-07-19T05:01:22","date_gmt":"2025-07-19T05:01:22","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/pfizer-stock-split-history\/"},"modified":"2025-07-19T05:01:22","modified_gmt":"2025-07-19T05:01:22","slug":"pfizer-stock-split-history","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/","title":{"rendered":"Pfizer Stock Split History: Complete Timeline"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\"><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":259834,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[16],"tags":[28,45,44],"class_list":["post-314268","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-data","tag-investment","tag-stock","tag-strategy"],"acf":{"h1":"Pfizer Stock Split History","h1_source":{"label":"H1","type":"text","formatted_value":"Pfizer Stock Split History"},"description":"Pfizer stock split history explained with comprehensive data and analysis. Unlock hidden PFE stock split patterns today for smarter investment decisions with Pocket Option.","description_source":{"label":"Description","type":"textarea","formatted_value":"Pfizer stock split history explained with comprehensive data and analysis. Unlock hidden PFE stock split patterns today for smarter investment decisions with Pocket Option."},"intro":"Understanding Pfizer stock split history is crucial for investors seeking to maximize returns through one of healthcare's most established players. This analysis explores PFE's corporate actions timeline, split-adjusted valuation impacts, and what these historical patterns may indicate for future investment strategies.","intro_source":{"label":"Intro","type":"text","formatted_value":"Understanding Pfizer stock split history is crucial for investors seeking to maximize returns through one of healthcare's most established players. This analysis explores PFE's corporate actions timeline, split-adjusted valuation impacts, and what these historical patterns may indicate for future investment strategies."},"body_html":"<div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Comprehensive Pfizer Stock Split History: 1983-Present<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Tracking the&nbsp;Pfizer stock split history&nbsp;reveals five strategic moments when the pharmaceutical giant adjusted its share structure to maintain market accessibility. For investors using&nbsp;Pocket Option&nbsp;tools, these historical patterns provide critical investment benchmarks that continue influencing PFE's valuation metrics today.<\/p><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>Date<\/th><th>Split Ratio<\/th><th>Pre-Split Price<\/th><th>Post-Split Price<\/th><th>Market Catalyst<\/th><\/tr><\/thead><tbody><tr><td>June 30, 1983<\/td><td>2:1<\/td><td>$79.63<\/td><td>$39.82<\/td><td>Feldene market expansion<\/td><\/tr><tr><td>January 24, 1989<\/td><td>3:1<\/td><td>$76.12<\/td><td>$25.37<\/td><td>Procardia XL launch<\/td><\/tr><tr><td>April 29, 1991<\/td><td>2:1<\/td><td>$69.75<\/td><td>$34.88<\/td><td>Zoloft introduction<\/td><\/tr><tr><td>June 2, 1997<\/td><td>2:1<\/td><td>$97.25<\/td><td>$48.63<\/td><td>Lipitor breakthrough<\/td><\/tr><tr><td>June 30, 1999<\/td><td>3:1<\/td><td>$117.50<\/td><td>$39.17<\/td><td>Viagra market dominance<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>A $10,000 investment in Pfizer before its first 1983 split would have grown to approximately 3,600 shares today through the multiplicative effect of these five splits (multiplication factor: 2\u00d73\u00d72\u00d72\u00d73=72). This demonstrates how the&nbsp;PFE stock split history&nbsp;created substantial value through share accumulation, despite recent price fluctuations.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Why Pfizer Hasn't Split Its Stock Since 1999<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>The 25+ year absence of&nbsp;Pfizer stock splits&nbsp;reflects fundamental shifts in both corporate strategy and market dynamics:<\/p><\/div><div class='po-container po-container_width_article-sm article-content po-article-page__text'><ul class='po-article-page-list'><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Institutional ownership increased from 67% in 1999 to 74% by 2023, reducing retail accessibility concerns<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Fractional share investing eliminated the primary rationale for splits<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>2000-2010 share price decline of 40% removed split necessity<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Dividend growth strategy emerged with 18 consecutive annual increases<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Annual dividend payout grew from $0.46 per share in 2000 to $1.64 by 2023<\/li><\/ul><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>When analyzing whether \"did Pfizer stock split\" actions remain relevant today,&nbsp;Pocket Option&nbsp;investors should note that Pfizer's focus has decisively shifted toward dividend growth as its primary shareholder return mechanism. The company has returned over $140 billion to shareholders through dividends since its last split in 1999.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Investment Performance Across Split Eras<\/h2><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>Investment Period<\/th><th>Initial $10,000<\/th><th>Split-Adjusted Growth<\/th><th>Value in 2025<\/th><th>CAGR<\/th><th>Dividend Contribution<\/th><\/tr><\/thead><tbody><tr><td>1980-1999 (Split Era)<\/td><td>$10,000<\/td><td>Shares: 500 \u2192 18,000<\/td><td>$720,000<\/td><td>10.1%<\/td><td>22% of returns<\/td><\/tr><tr><td>2000-2025 (Post-Split Era)<\/td><td>$10,000<\/td><td>No splits (250 shares)<\/td><td>$10,000<\/td><td>0.0%<\/td><td>100% of returns<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>This stark performance contrast illustrates how the&nbsp;Pfizer stock split history&nbsp;coincided with the company's hypergrowth phase, while the current era has delivered value primarily through income rather than capital appreciation.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Comparing Pfizer's Split Strategy With Pharmaceutical Competitors<\/h2><\/div><div class='po-container po-container_width_article po-article-page__table'><div class='po-table'><table><thead><tr><th>Company<\/th><th>Splits Since 1980<\/th><th>Most Recent Split<\/th><th>Current P\/E Ratio<\/th><th>10-Year Return<\/th><th>Dividend Yield<\/th><\/tr><\/thead><tbody><tr><td>Pfizer (PFE)<\/td><td>5<\/td><td>1999<\/td><td>12.5x<\/td><td>78%<\/td><td>4.3%<\/td><\/tr><tr><td>Johnson &amp; Johnson (JNJ)<\/td><td>3<\/td><td>2001<\/td><td>15.2x<\/td><td>112%<\/td><td>3.1%<\/td><\/tr><tr><td>Eli Lilly (LLY)<\/td><td>2<\/td><td>1997<\/td><td>47.8x<\/td><td>923%<\/td><td>0.8%<\/td><\/tr><tr><td>Merck (MRK)<\/td><td>4<\/td><td>1999<\/td><td>17.3x<\/td><td>153%<\/td><td>2.7%<\/td><\/tr><\/tbody><\/table><\/div><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>This comparison reveals an industry-wide abandonment of splits, with Eli Lilly achieving exceptional returns despite maintaining a high share price. For&nbsp;Pocket Option&nbsp;users analyzing pharmaceutical investments, this suggests market sentiment has shifted toward valuing growth prospects over share price accessibility.<\/p><\/div><div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Will Pfizer Split Again? Key Indicators to Monitor<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>While predicting future&nbsp;Pfizer stock splits&nbsp;involves uncertainty, specific indicators would typically precede such a decision:<\/p><\/div><div class='po-container po-container_width_article-sm article-content po-article-page__text'><ul class='po-article-page-list'><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Share price consistently trading above $100 for 6+ months<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>P\/E ratio expansion to 20+ on forward earnings<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Successful commercialization of mRNA pipeline beyond COVID vaccines<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Trading volume decline of 20%+ suggesting retail investor barriers<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Multiple pharmaceutical peers implementing splits within a 12-month period<\/li><\/ul><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Pocket Option&nbsp;analysis tools can help investors monitor these specific thresholds that typically precede split decisions. However, given Pfizer's current $30-40 trading range and income-focused investor base, a near-term split appears highly unlikely.<\/p><\/div>[cta_button text=\"\"]<div class='po-container po-container_width_article-sm'><h2 class='po-article-page__title'>Conclusion: Leveraging Pfizer's Split History in Today's Investment Strategy<\/h2><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>The comprehensive&nbsp;Pfizer stock split history&nbsp;demonstrates how corporate actions once served as growth indicators during the company's expansion phase. For contemporary investors, Pfizer's transition to a dividend-focused model requires adjusted valuation approaches.<\/p><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Rather than anticipating future splits,&nbsp;Pocket Option&nbsp;users should evaluate Pfizer based on:<\/p><\/div><div class='po-container po-container_width_article-sm article-content po-article-page__text'><ul class='po-article-page-list'><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Dividend coverage ratio (currently 2.7x, indicating sustainability)<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Pipeline revenue potential ($25B+ in projected peak sales from current late-stage candidates)<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Post-COVID strategic positioning in key therapeutic areas<\/li><li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Share repurchase program execution ($4B remaining authorization)<\/li><\/ul><\/div><div class='po-container po-container_width_article-sm'><p class='po-article-page__text'>Understanding whether \"did Pfizer stock split\" patterns might resume requires recognizing that the company's maturation has fundamentally altered its capital allocation priorities. While historical splits multiplied shares 72-fold for early investors, today's shareholders benefit primarily from Pfizer's commitment to returning capital through steadily increasing dividends rather than share count adjustments.<\/p><\/div>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Comprehensive Pfizer Stock Split History: 1983-Present<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Tracking the&nbsp;Pfizer stock split history&nbsp;reveals five strategic moments when the pharmaceutical giant adjusted its share structure to maintain market accessibility. For investors using&nbsp;Pocket Option&nbsp;tools, these historical patterns provide critical investment benchmarks that continue influencing PFE&#8217;s valuation metrics today.<\/p>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Split Ratio<\/th>\n<th>Pre-Split Price<\/th>\n<th>Post-Split Price<\/th>\n<th>Market Catalyst<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>June 30, 1983<\/td>\n<td>2:1<\/td>\n<td>$79.63<\/td>\n<td>$39.82<\/td>\n<td>Feldene market expansion<\/td>\n<\/tr>\n<tr>\n<td>January 24, 1989<\/td>\n<td>3:1<\/td>\n<td>$76.12<\/td>\n<td>$25.37<\/td>\n<td>Procardia XL launch<\/td>\n<\/tr>\n<tr>\n<td>April 29, 1991<\/td>\n<td>2:1<\/td>\n<td>$69.75<\/td>\n<td>$34.88<\/td>\n<td>Zoloft introduction<\/td>\n<\/tr>\n<tr>\n<td>June 2, 1997<\/td>\n<td>2:1<\/td>\n<td>$97.25<\/td>\n<td>$48.63<\/td>\n<td>Lipitor breakthrough<\/td>\n<\/tr>\n<tr>\n<td>June 30, 1999<\/td>\n<td>3:1<\/td>\n<td>$117.50<\/td>\n<td>$39.17<\/td>\n<td>Viagra market dominance<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>A $10,000 investment in Pfizer before its first 1983 split would have grown to approximately 3,600 shares today through the multiplicative effect of these five splits (multiplication factor: 2\u00d73\u00d72\u00d72\u00d73=72). This demonstrates how the&nbsp;PFE stock split history&nbsp;created substantial value through share accumulation, despite recent price fluctuations.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Why Pfizer Hasn&#8217;t Split Its Stock Since 1999<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>The 25+ year absence of&nbsp;Pfizer stock splits&nbsp;reflects fundamental shifts in both corporate strategy and market dynamics:<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm article-content po-article-page__text'>\n<ul class='po-article-page-list'>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Institutional ownership increased from 67% in 1999 to 74% by 2023, reducing retail accessibility concerns<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Fractional share investing eliminated the primary rationale for splits<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>2000-2010 share price decline of 40% removed split necessity<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Dividend growth strategy emerged with 18 consecutive annual increases<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Annual dividend payout grew from $0.46 per share in 2000 to $1.64 by 2023<\/li>\n<\/ul>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>When analyzing whether &#8220;did Pfizer stock split&#8221; actions remain relevant today,&nbsp;Pocket Option&nbsp;investors should note that Pfizer&#8217;s focus has decisively shifted toward dividend growth as its primary shareholder return mechanism. The company has returned over $140 billion to shareholders through dividends since its last split in 1999.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Investment Performance Across Split Eras<\/h2>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>Investment Period<\/th>\n<th>Initial $10,000<\/th>\n<th>Split-Adjusted Growth<\/th>\n<th>Value in 2025<\/th>\n<th>CAGR<\/th>\n<th>Dividend Contribution<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1980-1999 (Split Era)<\/td>\n<td>$10,000<\/td>\n<td>Shares: 500 \u2192 18,000<\/td>\n<td>$720,000<\/td>\n<td>10.1%<\/td>\n<td>22% of returns<\/td>\n<\/tr>\n<tr>\n<td>2000-2025 (Post-Split Era)<\/td>\n<td>$10,000<\/td>\n<td>No splits (250 shares)<\/td>\n<td>$10,000<\/td>\n<td>0.0%<\/td>\n<td>100% of returns<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>This stark performance contrast illustrates how the&nbsp;Pfizer stock split history&nbsp;coincided with the company&#8217;s hypergrowth phase, while the current era has delivered value primarily through income rather than capital appreciation.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Comparing Pfizer&#8217;s Split Strategy With Pharmaceutical Competitors<\/h2>\n<\/div>\n<div class='po-container po-container_width_article po-article-page__table'>\n<div class='po-table'>\n<table>\n<thead>\n<tr>\n<th>Company<\/th>\n<th>Splits Since 1980<\/th>\n<th>Most Recent Split<\/th>\n<th>Current P\/E Ratio<\/th>\n<th>10-Year Return<\/th>\n<th>Dividend Yield<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Pfizer (PFE)<\/td>\n<td>5<\/td>\n<td>1999<\/td>\n<td>12.5x<\/td>\n<td>78%<\/td>\n<td>4.3%<\/td>\n<\/tr>\n<tr>\n<td>Johnson &amp; Johnson (JNJ)<\/td>\n<td>3<\/td>\n<td>2001<\/td>\n<td>15.2x<\/td>\n<td>112%<\/td>\n<td>3.1%<\/td>\n<\/tr>\n<tr>\n<td>Eli Lilly (LLY)<\/td>\n<td>2<\/td>\n<td>1997<\/td>\n<td>47.8x<\/td>\n<td>923%<\/td>\n<td>0.8%<\/td>\n<\/tr>\n<tr>\n<td>Merck (MRK)<\/td>\n<td>4<\/td>\n<td>1999<\/td>\n<td>17.3x<\/td>\n<td>153%<\/td>\n<td>2.7%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>This comparison reveals an industry-wide abandonment of splits, with Eli Lilly achieving exceptional returns despite maintaining a high share price. For&nbsp;Pocket Option&nbsp;users analyzing pharmaceutical investments, this suggests market sentiment has shifted toward valuing growth prospects over share price accessibility.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Will Pfizer Split Again? Key Indicators to Monitor<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>While predicting future&nbsp;Pfizer stock splits&nbsp;involves uncertainty, specific indicators would typically precede such a decision:<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm article-content po-article-page__text'>\n<ul class='po-article-page-list'>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Share price consistently trading above $100 for 6+ months<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>P\/E ratio expansion to 20+ on forward earnings<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Successful commercialization of mRNA pipeline beyond COVID vaccines<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Trading volume decline of 20%+ suggesting retail investor barriers<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Multiple pharmaceutical peers implementing splits within a 12-month period<\/li>\n<\/ul>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Pocket Option&nbsp;analysis tools can help investors monitor these specific thresholds that typically precede split decisions. However, given Pfizer&#8217;s current $30-40 trading range and income-focused investor base, a near-term split appears highly unlikely.<\/p>\n<\/div>\n    <div class=\"po-container po-container_width_article\">\n        <a href=\"\/en\/quick-start\/\" class=\"po-line-banner po-article-page__line-banner\">\n            <svg class=\"svg-image po-line-banner__logo\" fill=\"currentColor\" width=\"auto\" height=\"auto\"\n                 aria-hidden=\"true\">\n                <use href=\"#svg-img-logo-white\"><\/use>\n            <\/svg>\n            <span class=\"po-line-banner__btn\"><\/span>\n        <\/a>\n    <\/div>\n    \n<div class='po-container po-container_width_article-sm'>\n<h2 class='po-article-page__title'>Conclusion: Leveraging Pfizer&#8217;s Split History in Today&#8217;s Investment Strategy<\/h2>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>The comprehensive&nbsp;Pfizer stock split history&nbsp;demonstrates how corporate actions once served as growth indicators during the company&#8217;s expansion phase. For contemporary investors, Pfizer&#8217;s transition to a dividend-focused model requires adjusted valuation approaches.<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Rather than anticipating future splits,&nbsp;Pocket Option&nbsp;users should evaluate Pfizer based on:<\/p>\n<\/div>\n<div class='po-container po-container_width_article-sm article-content po-article-page__text'>\n<ul class='po-article-page-list'>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Dividend coverage ratio (currently 2.7x, indicating sustainability)<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Pipeline revenue potential ($25B+ in projected peak sales from current late-stage candidates)<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Post-COVID strategic positioning in key therapeutic areas<\/li>\n<li class='po-article-page__text po-article-page__text_no-margin po-list-lvl_1'>Share repurchase program execution ($4B remaining authorization)<\/li>\n<\/ul>\n<\/div>\n<div class='po-container po-container_width_article-sm'>\n<p class='po-article-page__text'>Understanding whether &#8220;did Pfizer stock split&#8221; patterns might resume requires recognizing that the company&#8217;s maturation has fundamentally altered its capital allocation priorities. While historical splits multiplied shares 72-fold for early investors, today&#8217;s shareholders benefit primarily from Pfizer&#8217;s commitment to returning capital through steadily increasing dividends rather than share count adjustments.<\/p>\n<\/div>\n"},"faq":[{"question":"When was Pfizer's last stock split?","answer":"Pfizer's most recent stock split occurred on June 30, 1999, when the company implemented a 3-for-1 split. Since then, Pfizer has not executed any additional stock splits over the past 25+ years, instead focusing on other shareholder value mechanisms like dividend growth and strategic acquisitions."},{"question":"How many times has Pfizer stock split in its history?","answer":"Pfizer has implemented five stock splits throughout its trading history. These splits occurred on: June 30, 1983 (2-for-1), January 24, 1989 (3-for-1), April 29, 1991 (2-for-1), June 2, 1997 (2-for-1), and June 30, 1999 (3-for-1)."},{"question":"How would 100 shares of Pfizer purchased before any splits be valued today?","answer":"If an investor had purchased 100 shares of Pfizer before its first recorded split in 1983, those shares would have multiplied to 3,600 shares through the subsequent stock splits (2\u00d73\u00d72\u00d72\u00d73 = 72 multiplication factor). The exact value would depend on Pfizer's current share price, but at approximately $40 per share, this position would be worth around $144,000."},{"question":"Why doesn't Pfizer split its stock anymore?","answer":"Pfizer has likely discontinued stock splits due to several factors: changing market preferences for higher-priced stocks among institutional investors, the rise of fractional share investing eliminating accessibility barriers, prioritization of dividend growth as a value mechanism, and periods of stock price performance that haven't necessitated splits to maintain accessibility."},{"question":"Could Pfizer implement a stock split in the future?","answer":"While possible, a future Pfizer stock split appears unlikely in the near term given current price levels and company strategy. Factors that might trigger reconsideration include: sustained share price appreciation above $100, management shift toward enhancing retail investor accessibility, breakthrough product success driving accelerated growth, or an industry trend toward splits among pharmaceutical peers."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"When was Pfizer's last stock split?","answer":"Pfizer's most recent stock split occurred on June 30, 1999, when the company implemented a 3-for-1 split. Since then, Pfizer has not executed any additional stock splits over the past 25+ years, instead focusing on other shareholder value mechanisms like dividend growth and strategic acquisitions."},{"question":"How many times has Pfizer stock split in its history?","answer":"Pfizer has implemented five stock splits throughout its trading history. These splits occurred on: June 30, 1983 (2-for-1), January 24, 1989 (3-for-1), April 29, 1991 (2-for-1), June 2, 1997 (2-for-1), and June 30, 1999 (3-for-1)."},{"question":"How would 100 shares of Pfizer purchased before any splits be valued today?","answer":"If an investor had purchased 100 shares of Pfizer before its first recorded split in 1983, those shares would have multiplied to 3,600 shares through the subsequent stock splits (2\u00d73\u00d72\u00d72\u00d73 = 72 multiplication factor). The exact value would depend on Pfizer's current share price, but at approximately $40 per share, this position would be worth around $144,000."},{"question":"Why doesn't Pfizer split its stock anymore?","answer":"Pfizer has likely discontinued stock splits due to several factors: changing market preferences for higher-priced stocks among institutional investors, the rise of fractional share investing eliminating accessibility barriers, prioritization of dividend growth as a value mechanism, and periods of stock price performance that haven't necessitated splits to maintain accessibility."},{"question":"Could Pfizer implement a stock split in the future?","answer":"While possible, a future Pfizer stock split appears unlikely in the near term given current price levels and company strategy. Factors that might trigger reconsideration include: sustained share price appreciation above $100, management shift toward enhancing retail investor accessibility, breakthrough product success driving accelerated growth, or an industry trend toward splits among pharmaceutical peers."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Stock Split History: Complete Timeline<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Stock Split History: Complete Timeline\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-19T05:01:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1840\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Tatiana OK\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatiana OK\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/\"},\"author\":{\"name\":\"Tatiana OK\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"headline\":\"Pfizer Stock Split History: Complete Timeline\",\"datePublished\":\"2025-07-19T05:01:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/\"},\"wordCount\":6,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp\",\"keywords\":[\"investment\",\"stock\",\"strategy\"],\"articleSection\":[\"Data\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/\",\"name\":\"Pfizer Stock Split History: Complete Timeline\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp\",\"datePublished\":\"2025-07-19T05:01:22+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp\",\"width\":1840,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Stock Split History: Complete Timeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\",\"name\":\"Tatiana OK\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"caption\":\"Tatiana OK\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/tatiana\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Stock Split History: Complete Timeline","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/","og_locale":"en_US","og_type":"article","og_title":"Pfizer Stock Split History: Complete Timeline","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/","og_site_name":"Pocket Option blog","article_published_time":"2025-07-19T05:01:22+00:00","og_image":[{"width":1840,"height":700,"url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp","type":"image\/webp"}],"author":"Tatiana OK","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatiana OK"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/"},"author":{"name":"Tatiana OK","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"headline":"Pfizer Stock Split History: Complete Timeline","datePublished":"2025-07-19T05:01:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/"},"wordCount":6,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp","keywords":["investment","stock","strategy"],"articleSection":["Data"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/","name":"Pfizer Stock Split History: Complete Timeline","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp","datePublished":"2025-07-19T05:01:22+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1742024349778-10891479-6.webp","width":1840,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/data\/pfizer-stock-split-history\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"Pfizer Stock Split History: Complete Timeline"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d","name":"Tatiana OK","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","caption":"Tatiana OK"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/tatiana\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":314271,"slug":"pfizer-stock-split-history","post_title":"Historique des Divisions d'Actions Pfizer : Chronologie Compl\u00e8te","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/data\/pfizer-stock-split-history\/"},"it_IT":{"locale":"it_IT","id":314272,"slug":"pfizer-stock-split-history","post_title":"Cronologia Completa degli Split Azionari di Pfizer","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/data\/pfizer-stock-split-history\/"},"pl_PL":{"locale":"pl_PL","id":314274,"slug":"pfizer-stock-split-history","post_title":"Historia podzia\u0142u akcji Pfizer: Pe\u0142na o\u015b czasu","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/data\/pfizer-stock-split-history\/"},"es_ES":{"locale":"es_ES","id":314269,"slug":"pfizer-stock-split-history","post_title":"Historial de Divisiones de Acciones de Pfizer: Cronolog\u00eda Completa","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/data\/pfizer-stock-split-history\/"},"th_TH":{"locale":"th_TH","id":314276,"slug":"pfizer-stock-split-history","post_title":"\u0e1b\u0e23\u0e30\u0e27\u0e31\u0e15\u0e34\u0e01\u0e32\u0e23\u0e41\u0e22\u0e01\u0e2b\u0e38\u0e49\u0e19\u0e02\u0e2d\u0e07 Pfizer: \u0e44\u0e17\u0e21\u0e4c\u0e44\u0e25\u0e19\u0e4c\u0e17\u0e31\u0e49\u0e07\u0e2b\u0e21\u0e14","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/data\/pfizer-stock-split-history\/"},"tr_TR":{"locale":"tr_TR","id":314273,"slug":"pfizer-stock-split-history","post_title":"Pfizer Hisse B\u00f6l\u00fcnme Tarih\u00e7esi: Tam Zaman \u00c7izelgesi","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/data\/pfizer-stock-split-history\/"},"vt_VT":{"locale":"vt_VT","id":314275,"slug":"pfizer-stock-split-history","post_title":"L\u1ecbch S\u1eed Chia T\u00e1ch C\u1ed5 Phi\u1ebfu Pfizer: D\u00f2ng Th\u1eddi Gian Ho\u00e0n Ch\u1ec9nh","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/data\/pfizer-stock-split-history\/"},"pt_AA":{"locale":"pt_AA","id":314270,"slug":"pfizer-stock-split-history","post_title":"Hist\u00f3rico de Desdobramento de A\u00e7\u00f5es da Pfizer: Cronograma Completo","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/data\/pfizer-stock-split-history\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/314268","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=314268"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/314268\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/259834"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=314268"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=314268"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=314268"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}